AGLE News and Press, Aeglea BioTherapeutics Inc. From 08/29/19

AUSTIN, Texas, Aug. 29, 2019 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company that engineers next-generation human enzymes to provide solutions for diseases with unmet medical need, today announced it will present new data on all 14 pati...

Aeglea BioTherapeutics (NASDAQ: AGLE ): Q2 GAAP EPS of -$0.55 misses by $0.07 . More news on: Aeglea BioTherapeutics, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

FDA Breakthrough Therapy Designation Received for Pegzilarginase in Treatment of Arginase 1 Deficiency Dosed First Patient in Global Pivotal Phase 3 PEACE Trial New Data from Arginase 1 Deficiency Phase 2 Extension Trial Expected in September 2019 AUSTIN, Texas, Aug. 06, 2019...

Today, we want to share our analysis of Aeglea BioTherapeutics ( AGLE ) with you. Recently, the company’s stock price grew by over 15% following the recent purchases by CEO Anthony G. Quinn. Aeglea BioTherapeutics offers an attractive combination of a debt-free balance sheet with ~50% o...

AUSTIN, Texas, July 24, 2019 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company that engineers next-generation human enzymes to provide solutions for diseases with unmet medical need, today announced that the U.S. Food and Drug Administra...

The following slide deck was published by Aeglea BioTherapeutics, Inc. in conjunction with this Read more ...

Topline Data from PEACE Anticipated in First Quarter of 2021 New Data from ARG1-D Phase 1/2 Extension Study Expected in September 2019 AUSTIN, Texas, June 03, 2019 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company that engineers...

AUSTIN, Texas, May 30, 2019 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company that engineers next-generation human enzymes to provide solutions for diseases with unmet medical need, today announced that Anthony G. Quinn, M.B. Ch.B, Ph.D.,...

Aeglea BioTherapeutics (NASDAQ: AGLE ): Q1 GAAP EPS of -$0.59 misses by $0.04. More news on: Aeglea BioTherapeutics, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

Statistically Significant Reductions in Plasma Arginine with Accompanying Clinical Improvements with Pegzilarginase in Phase 1/2 Reaffirm Pivotal Trial Design Gross Proceeds of $69 Million from February 2019 Public Offering Extends Cash Runway Through Q1 of 2021 Pivotal Phase 3 Tr...